Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 169 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Erythropoietin Clear all
Withdrawn Phase 2 Interventional

Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI

NCT02148367
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Erythropoietin
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 4 Interventional

DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)

NCT00224081
View directory record Official record
Conditions
Anemia, Iron-Deficiency, Kidney Failure, Chronic, Hemodialysis
Interventions
Sodium ferric gluconate,
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
29
States / cities
Bakersfield, California • Glendale, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Sep 30, 2026, 2:32 AM EDT
Withdrawn Phase 2 Interventional

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00715364
View directory record Official record
Conditions
Stroke
Interventions
NTx™-265: rhCG, then rEPO, Saline Placebo
Drug
Lead sponsor
Stem Cell Therapeutics Corp.
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Newport Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2011 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.

NCT00752791
View directory record Official record
Conditions
Anemia
Interventions
Peginesatide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Azusa, California • Los Angeles, California • Whittier, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Sep 30, 2026, 2:32 AM EDT
Recruiting Phase 1 Interventional

EVR and EPO for Liver Transplant Tolerance

NCT06832189
View directory record Official record
Conditions
Liver Transplant
Interventions
Everolimus, Epoetin alfa
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02892149
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
127
States / cities
Huntsville, Alabama • Mesa, Arizona • Pine Bluff, Arkansas + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01473420
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease
Interventions
Epoetin Hospira, Epogen Amgen
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
73
States / cities
Azusa, California • Bakersfield, California • Long Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

NCT00513240
View directory record Official record
Conditions
Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries, Aortic Arch Hypoplasia or Interruption
Interventions
Erythropoetin, Normal saline
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Day to 30 Days
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Sep 30, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD

NCT00372489
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Pine Bluff, Arkansas • Mountain View, California • Lauderdale Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2012 · Synced Sep 30, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study

NCT00589953
View directory record Official record
Conditions
Infant, Premature, Erythropoietin, Brain Injury, Intraventricular Hemorrhage, Periventricular Leukomalacia, Neurodevelopmental Outcomes, Randomized Clinical Trial
Interventions
Erythropoietin, Saline placebo
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
Up to 24 Hours
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 30, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

NCT00379912
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Azacitidine, Erythropoietin, Azacitidine (Monotherapy)
Drug
Lead sponsor
Larry Cripe, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Galesburg, Illinois • Indianapolis, Indiana • Lafayette, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

NCT02260193
View directory record Official record
Conditions
Anemia, End Stage Renal Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
El Granada, California • Long Beach, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Not applicable Interventional Results available

Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy

NCT01099202
View directory record Official record
Conditions
Leukemia
Interventions
Procrit (epoetin alfa)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2012 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01906489
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease
Interventions
AKB-6548, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 82 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 4 Interventional

Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

NCT00425126
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Epoetin Alfa
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2010 · Synced Sep 30, 2026, 2:32 AM EDT
Not listed Phase 2 Interventional

Treatment of Chronic Anemia With Epoetin Alfa in Elderly

NCT00337441
View directory record Official record
Conditions
Anemia
Interventions
Epoetin Alfa (drug)
Drug
Lead sponsor
Research and Education Foundation of Michael Reese Hospital
Other
Eligibility
65 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2006 · Synced Sep 30, 2026, 2:32 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Acute Erythropoietin on Hepcidin and Dietary Iron Absorption Following Military-relevant Exercise in Energy Deficit: Pilot Study

NCT07517562
View directory record Official record
Conditions
Iron Absorption
Interventions
Exercise test
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 30, 2026, 2:32 AM EDT
Recruiting Phase 1 Interventional

Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage

NCT05617833
View directory record Official record
Conditions
Intraventricular Hemorrhage of Prematurity
Interventions
MLT+EPO, Placebo
Combination Product · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Hours to 2 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
St. Petersburg, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 4 Interventional Results available

Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients

NCT01395823
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
ergocalciferol supplementation, placebo
Dietary Supplement · Other
Lead sponsor
Dialysis Clinic, Inc.
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Redding, California • Albany, Georgia • Shreveport, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

NCT00090753
View directory record Official record
Conditions
Anemia
Interventions
Methoxy Polyethylene Glycol-Epoetin Beta, Epoetin alfa, Epoetin beta, Darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
83
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 3 Interventional

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

NCT00058331
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa
Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
18
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 2 Interventional

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

NCT00053001
View directory record Official record
Conditions
Anemia, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
epoetin alfa, thalidomide
Biological · Drug
Lead sponsor
Fallon Clinic
Industry
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
2
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Sep 30, 2026, 2:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin

NCT01207778
View directory record Official record
Conditions
Prematurity
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
36 Months to 72 Months
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
3
States / cities
Albuquerque, New Mexico • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients

NCT02570854
View directory record Official record
Conditions
Anemia, Iron-Deficiency
Interventions
CSJ137, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
San Diego, California • Lakewood, Colorado • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 30, 2026, 2:32 AM EDT